Termination 15. 2. Vypovedanie Quintiles and/or Sponsor may terminate this Agreement for any reason effective immediately upon written notice. The Institution may terminate upon written notice if circumstances beyond the Institution’s reasonable control prevent completion of the Study, or if it reasonably determines that it is unsafe to continue the Study. Upon receipt of notice of termination make all reasonable efforts to minimize further costs, and Sponsor shall make a final payment for visits or milestones properly performed pursuant to this Agreement in the amounts specified in Attachment A; provided, however, that ten percent (10%) of this final payment will be withheld until final acceptance by Sponsor of all CRF pages and all data clarifications issued and satisfaction of all other applicable conditions set forth herein. If a material breach of this Agreement appears to have occurred and termination may be required, then, except to the extent that Study Subject safety may be jeopardized, Sponsor may suspend performance of all or part of this Agreement, including, but not limited to, subject enrollment. Slovakia Clinical Trial Agreement template-INSTITUTION based on Quintiles Global template – 15 April 2013, PI . Xxxxx Xxxxxxxx XX , Protocol MDV3100-10, Project Code: RWA08073 Quintiles alebo zadávateľ môžu túto zmluvu vypovedať z akéhokoľvek dôvodu s okamžitou účinnosťou písomnou výpoveďou. Zdravotnícke zariadenie môže túto zmluvu vypovedať písomnou výpoveďou, ak mu okolnosti mimo jeho primeranej kontroly zabraňujú v dokončení skúšania, alebo ak dospeje k odôvodnenému záveru, že pokračovanie v skúšaní nie je bezpečné. Po prevzatí písomnej výpovede zdravotnícke zariadenie vynaloží primerané úsilie na minimalizovanie ďalších nákladov. Zadávateľ poukáže poslednú platbu za návštevy alebo výkony riadne vykonané v súlade s touto zmluvou vo výške stanovenej v Prílohe A; desať percent (10%) tejto poslednej platby však bude zadržaných až do zadávateľovho konečného prevzatia všetkých stránok pacientskych záznamov (CRF) a všetkých vydaných vysvetliviek k údajom a do splnenia všetkých ďalších uplatniteľných podmienok tu stanovených. V prípade podozrenia na podstatné porušenie tejto zmluvy, ktoré by vyžadovalo jej vypovedanie, môže zadávateľ čiastočne alebo úplne pozastaviť plnenie tejto zmluvy, vrátane zaraďovania subjektov do Slovakia Clinical Trial Agreement template-INSTITUTION based on Quintiles Global template – 28March2012 skúšania, s výnimkou rozsahu, v ktorom by bola o...
Termination 15. Section 4.1 Early Termination of Agreement; Breach of Agreement 15 Section 4.2 Early Termination Notice 16 Section 4.3 Payment upon Early Termination 17
Termination 15. Section 4.1 Early Termination of Agreement; Breach of Agreement 15 Section 4.2 Early Termination Notice 16 Section 4.3 Payment Upon Early Termination 17 ARTICLE V. SUBORDINATION AND LATE PAYMENTS 17 Section 5.1 Subordination 17 Section 5.2 Late Payments by the Corporation 18 ARTICLE VI. TAX MATTERS; CONSISTENCY; COOPERATION 18 Section 6.1 Participation in the Corporation’s and the LLC’s Tax Matters 18 Section 6.2 Consistency 18 Section 6.3 Cooperation 18 ARTICLE VII. MISCELLANEOUS 18 Section 7.1 Notices 18 Section 7.2 Counterparts 19 Section 7.3 Entire Agreement; No Third Party Beneficiaries 19 Section 7.4 Governing Law 20 Section 7.5 Severability 20 Section 7.6 Assignments; Amendments; Successors; No Waiver 20 Section 7.7 Titles and Subtitles 21 Section 7.8 Resolution of Disputes 21 Section 7.9 Reconciliation 22 Section 7.10 Withholding 22 Section 7.11 Admission of the Corporation into a Consolidated Group; Transfers of Corporate Assets 23 Section 7.12 Confidentiality 23 Section 7.13 Change in Law 24 Section 7.14 Interest Rate Limitation 24 Section 7.15 Independent Nature of Rights and Obligations 24 Section 7.16 LLC Agreement 25 Section 7.17 Rules of Construction 25 Exhibits Exhibit A – Form of Joinder Agreement TAX RECEIVABLE AGREEMENT This TAX RECEIVABLE AGREEMENT, dated as of [ ] [ ], 2018, is hereby entered into by and among i3 Verticals, Inc., a Delaware corporation (the “Corporation”), i3 Verticals, LLC, a Delaware limited liability company (the “LLC”), and each of the Members from time to time party hereto. Capitalized terms used but not otherwise defined herein have the respective meanings set forth in Section 1.1.
Termination 15. (a) The Minister may at any time prior to the expiry of the Term, immediately terminate this PLA, without cause, upon written notice to the Manufacturer.
Termination 15. 4 You shall not assign, sublicense or otherwise transfer
Termination 15. 2.1 Sponsor may terminate this Agreement for any reason effective immediately upon written notice. 15.2.2 The Institution may terminate the Agreement following thirty (30) days’ prior written notice to IQVIA and Sponsor of a material breach by IQVIA or Sponsor of any of its representations or obligations under this Agreement, unless such breach is cured within such thirty (30) day period. If in Institution or Investigator’s reasonable judgment an imminent Study subject safety concern exists in the performance of the Study as required by the Protocol, Institution may suspend performance of the Study, shall immediately notify IQVIA and Sponsor of such Study subject safety concern, and shall provide details and documentation requested by Sponsor. If after sixty (60) days from such notice by Institution the safety concern has not been reasonably addressed or resolved, Institution or Investigator may terminate this Agreement upon written notice to IQVIA and Sponsor. 15.2.3 Upon receipt of notice of termination (with or without cause), the Institution shall immediately cease any subject recruitment, follow the specified termination procedures, ensure that any required subject follow-up procedures are completed, and make all reasonable efforts to minimize further costs. 15.2.4 In the event of termination according to Section 15.2.1 IQVIA shall make a final payment for visits or 15.1 Platnost Tato Smlouva nabývá platnosti a účinnosti k datu, kdy bude podepsána poslední smluvní stranou (“Datum účinnosti”) a zůstane v účinnosti až do data (včetně), kdy Místo provádění klinického hodnocení splní všechny své závazky uvedené v této Smlouvě po dokončení či předčasném ukončení v souladu s tímto Článkem 15 “Platnost & Ukončení platnosti”. 15.2
Termination 15. 1 TERMINATION OF THIS BASE AGREEMENT Either party may terminate this Base Agreement, without any cancellation charge, for a material breach of this Agreement by the other party or if the other party becomes insolvent or files or has filed against it a petition in bankruptcy ("Cause"), to the extent permitted by law. Such termination will be effective at the end of a thirty (30) day written notice period if the Cause remains uncured. Either party may terminate this Base Agreement without Cause when there are no outstanding SOW's or WA's.
Termination 15. 2 Ukončení platnosti IQVIA and/or Sponsor may terminate this Agreement for any reason effective immediately upon written notice. IQVIA a/nebo Zadavatel jsou oprávněni ukončit platnost této Smlouvy z jakéhokoli důvodu s okamžitou účinností neprodleně na základě doručení písemného oznámení. The Site may terminate upon written notice if at any time in the Investigator’s professional judgment, a material adverse safety concern Místo provádění klinického hodnocení je oprávněno ukončit platnost této Smlouvy písemným oznámením pokud kdykoli, na for the Study Subjects makes continued testing inadvisable. The Institution may terminate this Agreement in writing if, as a result of a hindrance beyond the control of the Institution, the Institution is rendered long-term incapable to complete the Study, without its main operation being hindered, which is the provision of healthcare services. The notice period shall be 30 days and shall start on the day following the day of its receipt by Sponsor, IQVIA and the the Investigator. Upon notice of termination or upon notice of suspension of the Study or this Agreement, Site shall immediately cease enrollment of subjects into the Study and, at the election of IQVIA shall (a) either (i) terminate the Agreement with respect to the enrolled subjects in an orderly and prompt manner and pursuant to consultation with IQVIA and Sponsor, including any required follow-up treatment with previously enrolled subjects, or (ii) transfer the enrolled subjects to another clinical site in accordance with IQVIA’ instructions. Sponsor or its designee shall have the right to assume full control of the terminated Study and Site shall turn over all Study Documentation and materials in its possession associated with the Study, as expeditiously as possible, and shall provide such other assistance as is necessary to ensure a smooth and orderly transition of the Study without any disruption of the Protocol and (b) Site shall make all reasonable efforts to minimize further costs, and IQVIA shall make a final payment for visits or milestones properly performed pursuant to this Agreement in the amounts specified in Attachment A. základě odborného úsudku Hlavního zkoušejícího, závažné obavy o bezpečnost Subjektů studie způsobí, že další testování bude nežádoucí. Zdravotnické zařízení je oprávněno ukončit tuto smlouvu písemnou výpovědí, jestliže v důsledku vzniku překážky, jež nastala nezávisle na jeho vůli, nebude Zdravotnické zařízení dlouhodobě schopno ...
Termination 15. 2.1 Sponsor may terminate this Agreement for any reason effective immediately upon written notice. 15.2.2 The Institution may terminate the Agreement following sixty (60) days’ prior written notice to IQVIA and Sponsor of a material breach by IQVIA or Sponsor of any of its representations or obligations under this Agreement, unless such breach is cured within such sixty (60) day period. If in Institution or Investigator’s reasonable judgment an imminent Study subject safety concern exists in the performance of the Study as required by the Protocol, Institution may suspend performance of the Study, shall immediately notify IQVIA and Sponsor of such Study subject safety concern, and shall provide details and documentation requested by Sponsor. If after sixty (60) days from such notice by Institution the safety concern has not been reasonably addressed or resolved, Institution or Investigator may terminate this Agreement upon written notice to IQVIA and Sponsor. a/nebo Zadavatele, podle toho, co je relevantní. Ani IQVIA ani Zadavatel nebudou mít jakoukoli odpovědnost vztahující se k benefitům, penzím, náhradám, nárokům k důchodovému připojištění, pracovněprávním odměnám, srážkovým či jiným pracovněprávním daním týkajícím se Poskytovatele zdravotních služeb nebo jeho zaměstnanců. 15. PLATNOST & UKONČENÍ PLATNOSTI 15.1
Termination 15. 1 If you wish to terminate this Agreement for any reason you must give the Company notice in writing. Subject to the provisions of clause 15.3(iii), the minimum Notice Period to be given by you is specified in the Schedule. 15.2 The Company may terminate your employment under this Agreement at any time: (i) by giving you notice in writing, in which case the provisions of either 15.3(i) or clause 15.11 will apply; (ii) summarily, without payment in lieu of notice or other compensation (except compensation earned through the date of such termination), if you are found by the Company to have: (a) committed gross misconduct, gross incompetence or repeat or continue any other material breach of your obligations under this Agreement; or (b) committed, been charged with or convicted of any criminal offence other than an offence which does not in the reasonable opinion of the Company affect your position under this Agreement; or LUXFER HOLDINGS PLC Xxxxxxxxx Xxxxxxx, 0 Xxxxxxxxx Xxxx, Xxxxxxx, X00 0XX May 17, 2017
